Scancell (LON:SCLP) Shares Down 3.2% - Here's Why

Key Points

• Scancell Holdings plc saw a decline of 3.2% in its stock price, trading at GBX 9.69 ($0.13), with a significant increase in trading volume by 44% compared to its average daily volume.
• The company has a market capitalization of £99.63 million and a negative price-to-earnings ratio of -461.54, indicating losses relative to earnings.
• Insider Martin Diggle acquired 4.4 million shares at an average cost of GBX 10 each, reflecting confidence in the company as insiders hold 14.23% of the stock.

Scancell Holdings plc (LON:SCLP - Get Free Report) was down 3.2% on Wednesday . The stock traded as low as GBX 9.60 ($0.13) and last traded at GBX 9.69 ($0.13). Approximately 1,336,894 shares traded hands during mid-day trading, an increase of 44% from the average daily volume of 925,977 shares. The stock had previously closed at GBX 10 ($0.13).

Scancell Price Performance

The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of -566.79. The business has a fifty day moving average of GBX 10.15 and a 200 day moving average of GBX 9.63. The firm has a market cap of £89.64 million, a P/E ratio of -415.29 and a beta of 0.35.

Insiders Place Their Bets

In other news, insider Martin Diggle acquired 102,236 shares of the firm's stock in a transaction dated Thursday, August 7th. The stock was purchased at an average price of GBX 11 per share, for a total transaction of £11,245.96. Insiders own 15.15% of the company's stock.

Scancell Company Profile

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.